507453-56-7

Basic information

• Product Name: Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-[3,5-dihydroxy-4-[(1-oxohexadecyl)oxy]phenyl]-3,4-dihydro-5, 7-dihydroxy-2H-1-benzopyran-3-yl ester
• CAS NO: 507453-56-7
• Molecular Formula: C38H48O12
• Molecular Weight: 696.792
• Mol File: 507453-56-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-[3,5-dihydroxy-4-[(1-oxohexadecyl)oxy]phenyl]-3,4-dihydro-5, 7-dihydroxy-2H-1-benzopyran-3-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-[3,5-dihydroxy-4-[(1-oxohexadecyl)oxy]phenyl]-3,4-dihydro-5, 7-dihydroxy-2H-1-benzopyran-3-yl ester(507453-56-7)
• EPA Substance Registry System: Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-[3,5-dihydroxy-4-[(1-oxohexadecyl)oxy]phenyl]-3,4-dihydro-5, 7-dihydroxy-2H-1-benzopyran-3-yl ester(507453-56-7)

Safety Data

• Hazardous Substances Data: 507453-56-7(Hazardous Substances Data)

Upstream product

• 2596-50-1 (-)-epigallocathechin gallate 
• 112-67-4 n-hexadecanoyl chloride 
• 693-38-9 vinyl palmitate 

Relevant articles and documents

Improved Stability and Targeted Cytotoxicity of Epigallocatechin-3-Gallate Palmitate for Anticancer Therapy

Although with high antioxidant activity, epigallocatechin-3-gallate (EGCG) was restricted by its poor chemical stability in practical applications. One of EGCG derivatives, EGCG palmitate, was synthesized with EGCG and palmitoyl chloride to overcome instability of EGCG. However, uncertainties still exist in chemical stability and cytotoxicity of EGCG palmitate, which are essential for further exploration in anticancer therapy. Our work aims to analyze the resistance of EGCG palmitate to oxidation and summarize its targeted inhibition efficiency on cancerous cells and normal cells. High-performance liquid chromatography analysis confirmed that EGCG palmitate remained stable in air and Dulbecco's modified eagle medium (DMEM) for a longer time than EGCG. Antioxidative and pro-oxidative effects of EGCG palmitate on treated cells are proposed through reactive oxygen species (ROS) detection, respectively. It reveals that pro-oxidants by H2O2 production can exert antiproliferative and proapoptotic effects on cancerous cells and stimulate autophagy, while an antioxidant relieves oxidative stress caused by superoxide as compared to normal cells. Consequently, targeted cytotoxicity is adopted by EGCG palmitate-treated cancerous cells. Results above manifest that EGCG palmitate possesses potential to serve as a promising prodrug in anticancer treatment.

MEMBRANE FUSION INHIBITOR

The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition